U.S. markets close in 5 hours 49 minutes
  • S&P 500

    4,318.42
    -1.64 (-0.04%)
     
  • Dow 30

    33,896.90
    -66.94 (-0.20%)
     
  • Nasdaq

    13,214.19
    +2.38 (+0.02%)
     
  • Russell 2000

    1,779.31
    +2.80 (+0.16%)
     
  • Crude Oil

    89.79
    -0.24 (-0.27%)
     
  • Gold

    1,944.50
    -1.10 (-0.06%)
     
  • Silver

    23.72
    -0.12 (-0.52%)
     
  • EUR/USD

    1.0599
    -0.0049 (-0.46%)
     
  • 10-Yr Bond

    4.5110
    +0.0730 (+1.64%)
     
  • GBP/USD

    1.2210
    -0.0031 (-0.25%)
     
  • USD/JPY

    148.8520
    +0.4920 (+0.33%)
     
  • Bitcoin USD

    26,137.52
    -451.47 (-1.70%)
     
  • CMC Crypto 200

    558.86
    -0.65 (-0.12%)
     
  • FTSE 100

    7,601.92
    -81.99 (-1.07%)
     
  • Nikkei 225

    32,678.62
    +276.21 (+0.85%)
     

Medivation, Astellas prostate cancer drug meets trial goals

Oct 22 (Reuters) - Medivation Inc and its Japanese partner Astellas Pharma Inc said a late-stage trial of their experimental prostate cancer drug met the main goal of improving patients' survival.

An independent safety committee monitoring the trial recommended the trial be stopped and patients be treated with the experimental drug enzalutamide, the companies said in a joint statement.